Resona Asset Management Co. Ltd. Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Resona Asset Management Co. Ltd. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 114,407 shares of the medical research company’s stock after buying an additional 1,832 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in Thermo Fisher Scientific were worth $55,990,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Assetmark Inc. lifted its holdings in Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after acquiring an additional 7,023 shares during the period. Mackenzie Financial Corp grew its stake in Thermo Fisher Scientific by 29.4% in the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after purchasing an additional 62,790 shares during the period. North Dakota State Investment Board purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $7,505,000. Quadrant Capital Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 30.9% in the 3rd quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock worth $6,924,000 after buying an additional 3,369 shares during the last quarter. Finally, EdgePoint Investment Group Inc. grew its position in Thermo Fisher Scientific by 5.0% during the third quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock valued at $673,529,000 after buying an additional 65,597 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $510.19 on Thursday. The firm’s 50 day moving average is $475.96 and its 200 day moving average is $516.68. The stock has a market capitalization of $189.60 billion, a P/E ratio of 28.05, a PEG ratio of 2.29 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 12 month low of $403.36 and a 12 month high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. Thermo Fisher Scientific’s revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on TMO. Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price target on the stock. Sanford C. Bernstein started coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective on the stock. Weiss Ratings downgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, June 29th. Finally, Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research note on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $601.61.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.